Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. PIMA541854

Invitrogen™ Inotuzumab Humanized Recombinant Human Monoclonal Antibody
GREENER_CHOICE

Catalog No. PIMA541854
Change view
Click to view available options
Quantity:
100 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA541854 100 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
This item is not returnable. View return policy
Catalog No. PIMA541854 Supplier Invitrogen™ Supplier No. MA541854
Add to Cart
Add to Cart
This item is not returnable. View return policy

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Inotuzumab ozogamicin is an antibody-pharmaceutical conjugate using linker and cytotoxic pharmaceutical technology similar to that developed for the ground-breaking treatment Mylotarg (Gemtuzumab ozogamicin), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukemia. Inotuzumab ozogamicin consists of a recombinant humanized IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent 4. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relapsing conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy 5.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Inotuzumab Humanized
Applications ELISA, SDS-Page
Classification Recombinant Monoclonal
Concentration 2.7 mg/mL
Conjugate Unconjugated
Formulation PBS with no preservative; pH 7.4
Gene Alias CMC-544
Host Species Human
Immunogen Human CD22.
Purification Method Protein A/G
Quantity 100 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Human
Content And Storage -20°C, Avoid Freeze/Thaw Cycles
Product Type Antibody
Form Liquid
Isotype IgG4 κ
Target Molecule Chemical
Show More Show Less

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.